



PTO/SB/21 (03-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Application Number	10/056,680
Filing Date	01/25/2002
First Named Inventor	T. Kosoglou et al.
Art Unit	1617
Examiner Name	Mojdeh Bahar
Attorney Docket Number	CV01492K

Total Number of Pages in This Submission

5

ENCLOSURES (Check all that apply)

- | | | |
|--|---|--|
| <input type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Fee Attached
<input type="checkbox"/> Amendment/Reply
<input type="checkbox"/> After Final
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Extension of Time Request
<input type="checkbox"/> Express Abandonment Request
<input checked="" type="checkbox"/> Information Disclosure Statement
<input type="checkbox"/> Certified Copy of Priority Document(s)
<input type="checkbox"/> Response to Missing Parts/Incomplete Application
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)
<input type="checkbox"/> Licensing-related Papers
<input type="checkbox"/> Petition
<input type="checkbox"/> Petition to Convert to a Provisional Application
<input type="checkbox"/> Power of Attorney, Revocation
Change of Correspondence Address
<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Request for Refund
<input type="checkbox"/> CD, Number of CD(s) _____ | <input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below):
Certificate of Mailing PTO/SB92 - 1 Page
PTO-1449 - 1 Pg. in dup.; (15) References |
|--|---|--|

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual	Ann Marie Cannoni, Reg. No. 35,972
Signature	
Date	11/25/2003

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: _____

Typed or printed

Signature

Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Application No.: 10/056,680

Filing Date: 01/25/2002

Applicant: T. Kosoglou et al.

Title: Combinations of Sterol Absorption Inhibitor(s) with Blood Modifier(s) for Treating Vascular Indications

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on 11/25/2003

Date

Signature

Ann Marie Cannoni, Reg. No. 35,972

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Documents enclosed:

Response Transmittal PTO/SB/21 - 1 Page
Information Disclosure Statement - 1 Page
PTO-1449 - 1 Pg. in dup.; (15) References
Certificate of Mailing PTO/SB92 - 1 Page
Post Card

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT CASE CV01492K

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

-----X
In re Application of:

T. Kosoglou et al.

For: **Combinations of Sterol Absorption
Inhibitor(s) with Blood Modifier(s)
for Treating Vascular Indications**

Serial No.: 10/056,680

Filed: 01/25/2002
-----X

: Examiner: **Mojdeh Bahar**

: Group Art Unit: **1617**

: Date: **November 25, 2003**

:
: Schering-Plough Corporation
: Kenilworth, New Jersey 07033-0530

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT


Sir:

It is requested that the documents listed on the accompanying PTO-1449 Form be considered and made of record in the above-identified patent application. A copy of each cited document is attached.

No fee is believed to be due, however, if any fee is due the Commissioner is authorized to charge **Deposit Account Number 19-0365** for any fees deemed necessary for consideration and entry of this Information Disclosure Statement into the file record.

Respectfully submitted,

SCHERING-PLOUGH CORPORATION


Ann Marie Cannoni
Reg. No., 35,972
Attorney for Applicants
(908) 298-5024

Sheet 1 of 1

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.:
CV01492KAPPLICATION NO.:
10/056,680APPLICANT:
T. Kosoglou et al.FILING DATE:
01/25/2002GROUP:
1617

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	6,030,990	02/29/00	Maeda et al.			
	AB	6,166,049	12/26/00	Smith et al.			
	AC	2003/0153541	08/14/03	Dudley et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	AD	WO 01/14351	03/01/01	PCT				
	AE	WO 01/34148	05/17/01	PCT				
	AF	WO 01/60807	08/23/01	PCT				
	AG	WO 02/064094	08/22/02	PCT				
	AH	WO 02/08188	01/31/02	PCT				
	AI	WO 02/26729	04/04/02	PCT				
	AJ	WO 03/039542	05/15/03	PCT				
	AJ	WO 03/074101	09/12/03	PCT				
	AL	WO 03/088962	10/30/03	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AM	Sorbera et al., Netoglitazone, <i>Drugs of the Future</i> , 2002, 27(2): 132-139
	AN	Michel Farnier, Nouvelles approches médicamenteuses dans le traitement des dyslipidémies, <i>MT Endocrinologie</i> , 2002, 4:252-259
	AO	Berger et al., Physiological and Therapeutic Roles of Peroxisome Proliferator-Activated Receptors, <i>Diabetes Technology & Therapeutics</i> , 2002, 4:163-174

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



DUPLICATE

Sheet 1 of 1

PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

ATTY. DOCKET NO.:

CV01492K

APPLICATION NO.:

10/056,680

APPLICANT:

T. K soglou t al.

FILING DATE:

01/25/2002

GROUP:

1617

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	6,030,990	02/29/00	Maeda et al.			
	AB	6,166,049	12/26/00	Smith et al.			
	AC	2003/0153541	08/14/03	Dudley et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	AD	WO 01/14351	03/01/01	PCT				
	AE	WO 01/34148	05/17/01	PCT				
	AF	WO 01/60807	08/23/01	PCT				
	AG	WO 02/064094	08/22/02	PCT				
	AH	WO 02/08188	01/31/02	PCT				
	AI	WO 02/26729	04/04/02	PCT				
	AJ	WO 03/039542	05/15/03	PCT				
	AJ	WO 03/074101	09/12/03	PCT				
	AL	WO 03/088962	10/30/03	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AM	Sorbera <i>et al.</i> , Netoglitzazone, <i>Drugs of the Future</i> , 2002, 27(2): 132-139
	AN	Michel Farnier, Nouvelles approches médicamenteuses dans le traitement des dyslipidémies, <i>MT Endocrinologie</i> , 2002, 4:252-259
	AO	Berger <i>et al.</i> , Physiological and Therapeutic Roles of Peroxisome Proliferator-Activated Receptors, <i>Diabetes Technology & Therapeutics</i> , 2002, 4:163-174

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.